On the other hand, a higher CYT-1/CYT-2 ratio (CYT-1 dominance) correlated with the most aggressive breast cancer subtypes such as Triple Negative (TN), and CYT-1 dominant, with patients having a worse prognosis even in the ER+ HER2- population. This evidence concerns the gene ERBB2 and breast cancer.